VEGF-A promotes the motility of human melanoma cells through the VEGFR1-PI3K/Akt signaling pathway.


Journal

In vitro cellular & developmental biology. Animal
ISSN: 1543-706X
Titre abrégé: In Vitro Cell Dev Biol Anim
Pays: Germany
ID NLM: 9418515

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 13 07 2022
accepted: 12 08 2022
pubmed: 24 8 2022
medline: 13 10 2022
entrez: 23 8 2022
Statut: ppublish

Résumé

Vascular endothelial growth factor A (VEGF-A) and its receptors (VEGFR1 and R2) play important roles in the progression of malignant melanoma through tumor angiogenesis. However, it is not clear whether the VEGF-A/VEGFR1 signaling pathway is involved in the proliferation and migration of melanoma cells. Thus, the effect of VEGF-A on cell migration was investigated in human melanoma cell lines. Of several splicing variants of VEGF-A, VEGF

Identifiants

pubmed: 35997849
doi: 10.1007/s11626-022-00717-3
pii: 10.1007/s11626-022-00717-3
pmc: PMC9550759
doi:

Substances chimiques

Antibodies, Neutralizing 0
Oligonucleotides, Antisense 0
Phosphatidylinositols 0
Vascular Endothelial Growth Factor A 0
Phosphatidylinositol 3-Kinase EC 2.7.1.137
Proto-Oncogene Proteins c-akt EC 2.7.11.1
Wortmannin XVA4O219QW

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

758-770

Subventions

Organisme : Grants-in-Aid for Scientific Research (C) from the Japanese Ministry of Education, Culture, Sports, Science and Technology
ID : 24593033
Organisme : Grants-in-Aid for Scientific Research (B) from the Japanese Ministry of Education, Culture, Sports, Science and Technology
ID : 18H03000

Informations de copyright

© 2022. The Author(s).

Références

Oncol Lett. 2010 Mar;1(2):253-259
pubmed: 22966290
In Vitro Cell Dev Biol Anim. 1996 Feb;32(2):69-71
pubmed: 8907117
Biochem J. 2001 Sep 1;358(Pt 2):465-72
pubmed: 11513746
Am J Surg. 1980 May;139(5):660-4
pubmed: 7468915
Oncogene. 2007 May 14;26(22):3113-21
pubmed: 17496910
Mol Diagn Ther. 2016 Feb;20(1):13-26
pubmed: 26597586
Curr Opin Cell Biol. 2012 Apr;24(2):277-83
pubmed: 22209238
Cancer Res. 2011 Feb 15;71(4):1474-85
pubmed: 21212411
Genes Cancer. 2011 Dec;2(12):1097-105
pubmed: 22866201
Angiogenesis. 2006;9(4):225-30; discussion 231
pubmed: 17109193
BMC Cancer. 2019 Jun 14;19(1):584
pubmed: 31200683
J Exp Med. 1987 Jun 1;165(6):1761-6
pubmed: 3585251
Methods Mol Biol. 2010;661:125-35
pubmed: 20811980
Cancer. 2009 Apr 15;115(8):1701-12
pubmed: 19197998
Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5819-23
pubmed: 1712106
Front Cell Dev Biol. 2021 Dec 16;9:764151
pubmed: 34977016
Cell. 2019 Mar 7;176(6):1248-1264
pubmed: 30849371
Int J Cancer. 1998 Feb 9;75(4):654-8
pubmed: 9466671
Methods Mol Biol. 2005;294:15-22
pubmed: 15576901
Cardiovasc Res. 2005 Feb 15;65(3):550-63
pubmed: 15664381
Cochrane Database Syst Rev. 2018 Feb 06;2:CD011123
pubmed: 29405038
Cell Death Differ. 2010 Mar;17(3):499-512
pubmed: 19834490
Neuro Oncol. 2016 Sep;18(9):1242-52
pubmed: 27009237
Cancers (Basel). 2014 Jul 07;6(3):1441-63
pubmed: 25003395
Neoplasma. 2009;56(4):284-90
pubmed: 19473053
Gastroenterology. 2000 Nov;119(5):1358-72
pubmed: 11054395
J Cell Physiol. 1999 Feb;178(2):235-46
pubmed: 10048588
J Invest Dermatol. 2000 Dec;115(6):1000-7
pubmed: 11121133
Curr Opin Cell Biol. 2015 Oct;36:13-22
pubmed: 26183445
Oncogene. 2003 May 19;22(20):3172-9
pubmed: 12789293
Curr Oncol Rep. 2018 Mar 23;20(3):28
pubmed: 29569184
Pigment Cell Melanoma Res. 2015 Jan;28(1):73-81
pubmed: 25256553
Mol Carcinog. 1997 Aug;19(4):243-53
pubmed: 9290701
Annu Rev Med. 2016;67:11-28
pubmed: 26473415
Cancer Genomics Proteomics. 2013 Mar-Apr;10(2):55-67
pubmed: 23603341
J Med Chem. 1999 Dec 30;42(26):5369-89
pubmed: 10639280
Pharmacol Res. 2018 Oct;136:97-107
pubmed: 30170190
Oncotarget. 2016 Nov 8;7(45):72868-72885
pubmed: 27655684
Genes (Basel). 2021 Sep 28;12(10):
pubmed: 34680938
J Biol Chem. 1990 Nov 15;265(32):19461-6
pubmed: 2246236
Biochem Biophys Res Commun. 1993 Feb 15;190(3):702-8
pubmed: 8439321
Cold Spring Harb Perspect Med. 2012 Aug 01;2(8):
pubmed: 22908198
Crit Rev Eukaryot Gene Expr. 2020;30(4):291-297
pubmed: 32894659
Oncol Rep. 2007 Feb;17(2):417-23
pubmed: 17203182
J Exp Med. 1976 Oct 1;144(4):873-81
pubmed: 978138
Front Cell Dev Biol. 2021 Mar 23;9:660609
pubmed: 33834026
Int J Cancer. 2011 Dec 15;129(12):2807-15
pubmed: 21544800
Pharmacol Res. 2017 Jun;120:116-132
pubmed: 28330784

Auteurs

Koichi Koizumi (K)

Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553, Japan.

Tomoaki Shintani (T)

Center of Oral Clinical Examination, Hiroshima University Hospital, Hiroshima, 734-8551, Japan.

Yasutaka Hayashido (Y)

Oral Maxillofacial Surgery, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. hayashiy@hiroshima-u.ac.jp.

Atsuko Hamada (A)

Oral Maxillofacial Surgery, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Mirai Higaki (M)

Oral Maxillofacial Surgery, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Yukio Yoshioka (Y)

Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553, Japan.

Akihiko Sakamoto (A)

Oral Maxillofacial Surgery, Hiroshima University Hospital, Hiroshima, 734-8551, Japan.

Souichi Yanamoto (S)

Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553, Japan.
Oral Maxillofacial Surgery, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Tetsuji Okamoto (T)

Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553, Japan.
Oral Maxillofacial Surgery, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
School of Medical Sciences, University of East Asia, Shimonoseki, 751-8503, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH